BioSpace
Patient Dies After Receiving Intellia’s CRISPR Gene Therapy Candidate
The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...
Intellia tumbles after patient dies following Crispr treatment
The Cambridge-based biotech company is studying the use of Crispr, the Nobel Prize-winning gene-editing technology, to treat ...
Reuters
Intellia pauses gene therapy trials after patient suffers liver injury, shares slide
Oct 27 (Reuters) - Intellia Therapeutics (NTLA.O), opens new tab has temporarily stopped dosing and patient screening in two late-stage studies of its gene therapy after a participant ...
STAT
Intellia pauses two late-stage CRISPR gene-editing trials after emergence of safety concern
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
Fierce Biotech
Patient dies after receiving Intellia's CRISPR therapy
The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...